Trending Topics in Gastroenterology | GastroAGI

VOCAL-Penn score

The VOCAL-Penn score (VPS) is a medical risk prediction tool developed in 2021 to estimate postoperative mortality and decompensation risk in patients with cirrhosis undergoing surgical procedures. It is widely adopted in clinical practice, with over 15,000 users annually, and has been incorporated into major national and international society guidelines. ### Key Features of the VOCAL-Penn Score: 1. **Purpose**: The VPS helps clinicians assess the risks associated with surgery in patients with cirrhosis, a population that often faces higher surgical risks due to their complex medical condition. 2. **Clinical Use**: The tool is designed to support surgical decision-making by providing accurate predictions of postoperative outcomes, enabling clinicians to better stratify risk and guide treatment plans. 3. **Adoption**: Since its introduction, the VPS has achieved significant real-world uptake, indicating its utility and credibility among healthcare providers. ### Factors Supporting Its Adoption: The VOCAL-Penn score has been successful due to its alignment with five key design and implementation factors identified through clinician feedback: 1. **Efficiency**: The tool is intuitive, requires minimal inputs, and integrates seamlessly into clinical workflows. 2. **Accessibility**: Input variables are clinically meaningful and readily available, making the tool easy to use in practice. 3. **Transparency**: The development process of the VPS is transparent, fostering trust among clinicians. 4. **Accuracy**: Comparative performance data and external validations ensure the tool’s credibility and reliability. 5. **Generalizability**: The score is applicable across diverse patient populations, supporting equitable use. ### Context of Development: The VPS was developed during a time when advancements in data science, electronic health records, and machine learning were driving the proliferation of medical prediction tools. Despite the availability of such tools, many faced challenges in achieving sustained clinical adoption due to usability and implementation issues. The VPS stands out as an example of a prediction model that successfully bridges the gap between statistical rigor and practical usability. ### Research Insights: A qualitative study involving 22 diverse clinicians who care for cirrhosis patients highlighted the importance of aligning risk prediction tools like the VPS with real-world clinical needs. Clinicians emphasized that tools should be easy to use, credible, and seamlessly integrated into existing workflows to encourage adoption. ### Conclusion: The VOCAL-Penn score serves as a model for designing effective medical risk prediction tools. By addressing practical factors such as efficiency, accessibility, transparency, accuracy, and generalizability, the VPS has achieved widespread use and has provided valuable insights for developing future tools. Its success demonstrates the importance of considering both statistical performance and real-world implementation needs in the design of clinical prediction models.

Adrenal Dysfunction and HPA Axis Impairment in Decompensated Cirrhosis

Adrenal dysfunction (AD) and hypothalamic–pituitary–adrenal (HPA) axis impairment are important yet poorly understood phenomena in patients with decompensated cirrhosis, particularly in stable, non-hospitalized individuals. The study you referenced provides valuable insights into the prevalence, underlying mechanisms, and clinical implications of AD in this patient population. ### Key Findings: 1. **Prevalence of Adrenal Dysfunction**: - AD was identified in 33% of stable outpatients with Child-Pugh B or C cirrhosis using adrenocorticotropic hormone (ACTH) stimulation testing. AD was defined as a delta cortisol increase of less than 9 µg/dL following ACTH stimulation. 2. **Mechanisms of Adrenal Dysfunction**: - Despite impaired cortisol responses in patients with AD, their baseline ACTH levels were not elevated. This finding suggests that the dysfunction is likely due to inappropriate central HPA axis signaling (secondary adrenal insufficiency) rather than primary adrenal gland failure. - Biochemical analysis revealed impaired adrenal steroidogenesis, as evidenced by a significantly reduced 17-hydroxyprogesterone to 11-deoxycortisol ratio. This suggests potential inefficiency in enzymatic pathways involved in cortisol synthesis. - Inflammatory markers, such as interleukin-6 (IL-6), were significantly higher in patients with AD. IL-6 levels were inversely correlated with cortisol response, indicating that immune-mediated inflammation may modulate or impair the HPA axis. 3. **Clinical Implications**: - Over a 12-month follow-up period, AD was not associated with worse clinical outcomes, including mortality, hospitalization, liver transplantation, or portal hypertension-related decompensation. - These findings suggest that AD in stable outpatients with decompensated cirrhosis represents a form of extrahepatic organ dysfunction linked to cirrhosis, rather than a primary driver of short-term adverse outcomes. 4. **Prognostic Significance**: - Unlike in critically ill cirrhotic patients, adrenal dysfunction in stable outpatients does not appear to have significant prognostic implications in the short term. - The study highlights the need for additional research to explore the potential long-term consequences of AD and whether interventions targeting the HPA axis could improve outcomes. ### Mechanistic Insight: - This study emphasizes the multilevel impairment of the HPA axis in decompensated cirrhosis. The dysfunction appears to involve central signaling abnormalities, enzymatic inefficiencies in cortisol synthesis, and immune system interactions. - The elevated IL-6 levels and their inverse correlation with cortisol response provide evidence for immune-mediated modulation of the HPA axis, which may play a role in the pathophysiology of AD in this population. ### Research Implications: - The findings underscore the importance of further longitudinal studies to determine the long-term impact of adrenal dysfunction in cirrhosis. - Interventional studies may also be needed to assess whether addressing HPA axis impairment or modulating inflammation can improve clinical outcomes in this population. ### Conclusion: Adrenal dysfunction in decompensated cirrhosis is a complex, multifactorial condition involving central HPA axis impairment, altered adrenal steroidogenesis, and immune system interactions. While it is prevalent among stable outpatients, it does not appear to significantly influence short-term outcomes such as mortality or hospitalization. The study provides a foundation for further research into the mechanisms and potential therapeutic strategies for managing AD in cirrhosis.

Incidence and Clinical Significance of Recompensation After HCV Cure

The incidence and clinical significance of recompensation after hepatitis C virus (HCV) cure in patients with decompensated cirrhosis have been a focus of detailed analysis. Here is a comprehensive breakdown based on the given context: ### **Incidence of Recompensation** 1. **Recompensation Rate**: Among patients with decompensated cirrhosis who achieved sustained virologic response (SVR) following direct-acting antiviral (DAA) therapy, approximately **36.6%** achieved recompensation during the follow-up period. This indicates that over one-third of these patients experienced significant clinical improvement. 2. **Time to Recompensation**: The median time to achieve recompensation was **under two years** after HCV cure, suggesting that clinical improvement can occur relatively early following viral eradication. 3. **Definition of Recompensation**: Recompensation was defined using the Baveno VII criteria, which required: - Etiological cure of HCV. - Resolution of ascites and hepatic encephalopathy without medication. - No variceal bleeding for a minimum duration of 12 months. ### **Clinical Significance of Recompensation** Recompensation is clinically significant as it leads to substantial improvements in patient outcomes, although it does not fully restore the risk profile to the level of compensated advanced chronic liver disease (ACLD). 1. **Reduced Liver-Related Mortality**: Achieving recompensation was associated with a **markedly lower risk of liver-related death** compared to patients who remained decompensated. This highlights the potential for improved survival outcomes. 2. **Improved Overall Survival**: Overall mortality was significantly lower in recompensated patients. However, their survival rates did not reach those of patients with compensated ACLD, indicating that recompensated patients still carry residual risks. 3. **Lower Risk of Portal Vein Thrombosis (PVT)**: Recompensated patients had a **substantially reduced incidence of portal vein thrombosis** compared with non-recompensated individuals. This suggests that recompensation has a positive impact on vascular complications. 4. **Persistent Risk of Hepatocellular Carcinoma (HCC)**: Despite achieving recompensation, the risk of developing hepatocellular carcinoma (HCC) remained **significant** and comparable to that of patients with decompensated cirrhosis. This underscores the need for continued HCC surveillance. 5. **Intermediate Risk Profile**: Recompensated patients demonstrated an **intermediate risk profile** between compensated ACLD and decompensated cirrhosis across major clinical endpoints, such as mortality and complications. 6. **Further Decompensation Risk**: Nearly **one-fifth (20%)** of recompensated patients experienced subsequent redecompensation during follow-up. This indicates that recompensation is not always durable, and vigilance is required even after clinical improvement. ### **Predictors and Barriers to Recompensation** 1. **Positive Predictor - Serum Albumin**: Higher serum albumin levels were independently associated with a greater likelihood of achieving recompensation. Albumin is a key marker of liver function and overall health status. 2. **Negative Predictor - Diabetes**: The presence of diabetes significantly reduced the probability of recompensation after HCV cure. This suggests that metabolic comorbidities can hinder clinical improvement. 3. **MELD Score Not Predictive**: The Model for End-Stage Liver Disease (MELD) score, commonly used to assess liver disease severity, did not independently predict recompensation or long-term outcomes after viral eradication. 4. **HCC as a Barrier**: Development of de novo hepatocellular carcinoma (HCC) prevented recompensation, as no patient achieved recompensation after the onset of HCC. 5. **Alcohol Use**: Ongoing alcohol consumption remained a concern even after HCV cure, potentially limiting the benefits of recompensation and increasing the risk of liver-related complications. ### **Long-Term Management Implications** 1. **Surveillance and Monitoring**: Recompensated patients cannot be managed like those with compensated ACLD due to persistently elevated risks of complications such as HCC and redecompensation. Continued **surveillance for HCC and other complications** is essential. 2. **Alcohol Abstinence**: Addressing alcohol use is critical to maximizing the benefits of recompensation and reducing the risk of further liver damage. 3. **Tailored Clinical Management**: Recompensated patients require individualized management strategies to address their intermediate risk profile and prevent further decompensation. 4. **Durability of Outcomes**: Long-term follow-up (median exceeding eight years in the study) is crucial to assess the durability of recompensation and to identify patients at risk of redecompensation or other adverse outcomes. ### **Conclusion** Recompensation after HCV cure is a clinically significant outcome, offering substantial improvements in survival, reduced liver-related mortality, and lower risk of complications like portal vein thrombosis. However, recompensation does not eliminate all risks, as patients remain vulnerable to hepatocellular carcinoma, redecompensation, and other complications. Continued surveillance and tailored clinical management are essential for optimizing outcomes in this patient population.

Early Hepatic Encephalopathy After TIPS Is Associated With Reduced Survival

Yes, early hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) placement is strongly associated with reduced survival. This conclusion is supported by a large multicenter analysis involving 1,356 patients with cirrhosis who underwent TIPS placement across eight German tertiary centers. The study followed patients longitudinally for up to 30 months to evaluate HE occurrence and survival outcomes, providing critical insights into the timing and prognostic significance of HE. ### Key Findings: 1. **Impact of Early HE on Survival**: - Early HE, defined as episodes occurring within 30 days after TIPS insertion, was strongly associated with impaired survival compared to patients who did not develop HE. - The negative prognostic impact of HE was driven entirely by these early episodes, highlighting their clinical importance. 2. **Late HE Not Harmful**: - HE occurring after 30 days post-TIPS did not worsen survival, suggesting that the timing of HE is crucial in determining its prognostic significance. 3. **Landmark Analysis Confirmation**: - Thirty- and ninety-day landmark analyses confirmed early HE as an independent predictor of mortality, reinforcing its role in survival outcomes. 4. **Severity of HE**: - The survival outcomes did not differ significantly between patients with grade 2 HE versus grade 3–4 HE. This indicates that the occurrence of early HE itself, rather than its severity, is the critical factor impacting survival. 5. **Pre-TIPS HE and Survival**: - A history of HE before TIPS was an independent predictor of worse post-TIPS survival. Patients who had both pre-TIPS HE and early post-TIPS HE demonstrated the poorest survival outcomes, identifying them as the highest-risk group. 6. **Risk Factors for Early HE**: - Several factors increased the risk of developing early HE, including: - Older age. - Impaired renal function. - Hyponatremia. - Higher MELD (Model for End-Stage Liver Disease) score. - Prior history of HE. 7. **Portal Pressure Reduction**: - The hemodynamic response to TIPS, specifically portal pressure reduction, was similar regardless of HE development, suggesting that early HE reflects overall patient vulnerability rather than being a direct cause of mortality. ### Clinical Implications: - **Monitoring and Follow-Up**: - Patients with pre-TIPS HE or early post-TIPS HE require intensified monitoring and follow-up to address their heightened risk of mortality. - **Prognostic Scores**: - Current prognostic scores like MELD and FIPS do not fully account for the timing of HE, indicating the need for improved tools to assess risk in patients undergoing TIPS. - **Global Vulnerability Marker**: - Early HE may serve as a marker of global patient vulnerability rather than a direct cause of death, emphasizing the importance of identifying and managing underlying factors contributing to HE. ### Conclusion: Early HE after TIPS is a critical prognostic factor associated with reduced survival. Identifying high-risk patients, such as those with pre-TIPS HE or early post-TIPS HE, and implementing tailored management strategies are essential to improve outcomes after TIPS placement.

AGA Clinical Practice Update on Ascites, Volume Overload, and Hyponatremia in Cirrhosis

The American Gastroenterological Association (AGA) Clinical Practice Update on Ascites, Volume Overload, and Hyponatremia in Cirrhosis provides evidence-based guidance on the management of these complications in patients with cirrhosis. Below is a detailed summary of the key points from the update: ### **1. Volume Overload in Cirrhosis** - **Hallmarks:** Ascites, hepatic hydrothorax, peripheral edema, and anasarca are defining features of decompensated cirrhosis caused by portal hypertension. - **Pathophysiology:** Portal hypertension leads to neurohormonal activation, which drives renal sodium and water retention, intravascular hypovolemia, and fluid redistribution. - **Impact on Quality of Life:** Volume overload is associated with frequent hospitalizations, reduced quality of life, and increased mortality. ### **2. Ascites Management** - **First-Line Treatment:** - **Dietary Sodium Restriction:** Sodium restriction is critical for managing ascites. Early referral to a dietitian is recommended to ensure adequate nutrition while achieving sodium restriction. - **Diuretics:** Spironolactone and furosemide are used in combination, typically in a 100:40 mg ratio, to improve natriuresis while maintaining electrolyte balance. - **Weight Targets for Diuresis:** - Safe diuresis targets are 0.5 kg/day in patients without peripheral edema and up to 1 kg/day in patients with peripheral edema. - **Diagnostic Paracentesis:** - All hospitalized patients with new or worsening ascites should undergo prompt diagnostic paracentesis to evaluate for spontaneous bacterial peritonitis (SBP). - Ascitic fluid analysis (cell count and cultures) is essential for diagnosing SBP, even in asymptomatic patients. - **Refractory Ascites:** - Defined as ascites that is unresponsive or intolerant to diuretics and requires repeated therapeutic paracentesis. - Intravenous albumin is recommended when removing more than 5 L of ascites to prevent circulatory dysfunction. - **TIPS Procedure:** - Transjugular intrahepatic portosystemic shunt (TIPS) should be considered for selected patients with refractory ascites, hepatic hydrothorax, or hyponatremia. ### **3. Hepatic Hydrothorax** - **Prognosis:** Hepatic hydrothorax is associated with worse outcomes compared to refractory ascites. - **Management:** - Symptomatic hepatic hydrothorax requires thoracentesis for both diagnostic purposes and symptom relief. - **Transplant Referral:** All patients with hepatic hydrothorax should be evaluated for liver transplantation, irrespective of their MELD score. ### **4. Hyponatremia in Cirrhosis** - **Prevalence and Pathophysiology:** Hyponatremia in cirrhosis is usually hypervolemic and reflects advanced circulatory dysfunction. - **Diagnostic Workup:** Comprehensive evaluation includes assessing medications, renal function, infections, and endocrine disorders. - **Management:** - **Outpatient Care:** Asymptomatic patients can be managed with fluid restriction, diuretic adjustments, and close monitoring. - **Inpatient Care:** Severe or symptomatic hyponatremia requires hospitalization, fluid restriction, intravenous albumin, or vasoconstrictors. - **Multidisciplinary Approach:** Refractory hyponatremia requires coordinated care involving hepatology, nephrology, and transplant teams. ### **5. Liver Transplantation** - **Universal Referral:** All patients with ascites or hepatic hydrothorax should be evaluated for liver transplantation, regardless of their MELD score. ### **6. Multidisciplinary Management** - Patients with refractory volume overload or hyponatremia benefit from a collaborative approach involving hepatologists, nephrologists, dietitians, and transplant teams for optimal care. ### **Conclusion** The AGA guidelines emphasize a structured approach to managing ascites, volume overload, and hyponatremia in cirrhosis. Early intervention, patient-centered care, and multidisciplinary collaboration are essential to improve outcomes and quality of life for affected patients.

Circulating microbiome profiling in transjugular intrahepatic portosystemic shunt patients: 16S rRNA vs. shotgun sequencing

The study focused on comparing the performance of 16S rRNA sequencing and shotgun metagenomic sequencing for profiling the circulating microbiome in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS) procedures. Below is a detailed breakdown of the findings and implications: ### **Clinical Context** - Profiling the circulating microbiome in blood samples is inherently challenging due to **low microbial biomass** and **high host DNA contamination**, which can obscure microbial signals. - The TIPS procedure, which creates a shunt between the portal and systemic circulation, provides a unique opportunity to simultaneously collect blood samples from the **portal vein**, **hepatic vein**, and **peripheral vein**, reducing inter-individual variability and allowing for more robust comparisons of the circulating microbiome. --- ### **Comparison of 16S rRNA Sequencing vs. Shotgun Metagenomic Sequencing** #### **1. Sensitivity and Detection** - **16S rRNA sequencing** demonstrated **greater sensitivity** in detecting microbial signals in blood samples compared to shotgun metagenomics. - It was particularly effective in identifying **low-abundance and rare microbial taxa**, which are often missed by shotgun sequencing. - Shotgun metagenomics faced significant limitations due to **high host DNA interference**, which reduced its ability to detect microbial DNA effectively. #### **2. Taxonomic Coverage** - **16S rRNA sequencing** provided **broader taxonomic coverage**, identifying a wider range of microbial taxa. - Shotgun sequencing was limited in its ability to detect a diverse microbial community, partly due to its susceptibility to host DNA contamination. #### **3. Method-Specific Bias** - There was **low concordance** between the taxonomic profiles generated by the two methods, indicating method-dependent biases. - Many microbial genera were uniquely detected by 16S rRNA sequencing, while some were exclusively identified by shotgun sequencing, though these were sporadic and inconsistently present across samples. - Primer mismatches in 16S rRNA sequencing explained why certain taxa detected by shotgun sequencing were absent in 16S datasets. #### **4. Detection Depth** - 16S rRNA sequencing reached sufficient detection depth more efficiently than shotgun metagenomics, making it more practical for analyzing low-biomass samples like blood. --- ### **Microbial Diversity and Composition** #### **1. Alpha Diversity (Within-Sample Diversity)** - Microbial diversity within blood samples remained **stable across different vascular compartments** (portal, hepatic, and peripheral veins). #### **2. Beta Diversity (Between-Sample Diversity)** - The composition of microbial communities did not significantly differ between the portal, hepatic, and peripheral blood compartments, suggesting a **homogeneous circulating microbiome** across these regions. #### **3. Core Microbiota** - Both sequencing methods consistently detected a **shared core microbiota**, further supporting the stability and uniformity of the circulating microbiome across different blood compartments. --- ### **Peripheral Blood as a Representative Sample** - Peripheral blood was found to reliably represent the **systemic circulating microbiota**, making it a convenient and accessible sample source for future microbiome studies. --- ### **Clinical and Translational Implications** #### **1. Feasibility for Clinical Use** - **16S rRNA sequencing** emerged as a more **practical, cost-effective, and sensitive** method for clinical studies of the circulating microbiome, particularly in low-biomass samples like blood. - Shotgun metagenomics, while comprehensive in other contexts, was less suitable for blood microbiome studies due to its susceptibility to host DNA contamination and lower sensitivity. #### **2. Future Research Directions** - The findings support the use of **16S rRNA sequencing** and **peripheral blood sampling** in future studies of the circulating microbiome. - The ability of 16S rRNA sequencing to detect low-abundance taxa and provide broader taxonomic coverage makes it especially valuable for investigating the role of the microbiome in systemic diseases and conditions associated with TIPS patients. --- ### **Conclusion** The study highlights the superiority of **16S rRNA sequencing** over shotgun metagenomics for profiling the circulating microbiome in TIPS patients. It offers greater sensitivity, broader taxonomic coverage, and better feasibility for clinical applications. Peripheral blood sampling was validated as a reliable and representative approach for systemic microbiome studies, paving the way for translational research into the role of the circulating microbiome in health and disease.

ACLF—Contrasting Perspectives From the East and West

Acute-on-chronic liver failure (ACLF) is a severe condition characterized by acute decompensation in patients with chronic liver disease, accompanied by organ failures and high short-term mortality. However, the definitions, triggers, and management strategies for ACLF differ significantly between Eastern (Asia–Pacific) and Western perspectives. Below is a detailed comparison of the contrasting approaches from the East and West: --- ### **1. Definitions: APASL vs AASLD/CLIF** #### **Eastern Perspective: APASL (Asia–Pacific Association for the Study of the Liver)** - **Definition**: ACLF is primarily defined as an *acute hepatic insult* in a patient with chronic liver disease or compensated cirrhosis. This insult leads to: - **Jaundice** (bilirubin ≥5 mg/dL) - **Coagulopathy** (INR ≥1.5) - Complications within 4 weeks, including **ascites** and/or **encephalopathy**. - **Focus**: Liver failure is considered the primary event, with extrahepatic organ dysfunction being secondary. - **Triggers**: Common acute hepatic insults include: - Flare of hepatitis B virus (HBV) - Acute alcoholic hepatitis - Drug-induced liver injury - Infection - **Approach**: The definition emphasizes liver-centric failure and its progression to multi-organ dysfunction. #### **Western Perspective: AASLD/CLIF (American Association for the Study of Liver Diseases / Chronic Liver Failure Consortium)** - **Definition**: ACLF is defined in patients with *decompensated cirrhosis* based on the presence of **organ failures**, assessed using: - **CLIF-SOFA/CLIF-OF score**, which evaluates: - Liver function - Kidney function - Brain function - Coagulation - Circulation - Respiration - Associated 28-day mortality risk is a key component of the definition. - **Focus**: ACLF is considered a **multiorgan failure syndrome** in cirrhosis, where organ dysfunctions occur simultaneously. - **Triggers**: Common triggers include: - Infection (e.g., spontaneous bacterial peritonitis) - Active alcohol use - Gastrointestinal bleeding - **Approach**: The definition highlights systemic involvement and multiorgan failure. --- ### **2. Management: East vs West** #### **Western Perspective: AASLD/EASL-CLIF** - **Early ICU-Level Care**: Patients with ACLF are often admitted to intensive care units for close monitoring and aggressive interventions. - **Sepsis Control**: Infection is a frequent trigger, and early, aggressive management of sepsis is emphasized. - **Renal Replacement Therapy (RRT)**: For acute kidney injury or hepatorenal syndrome. - **Vasopressors**: Used to manage circulatory dysfunction and maintain hemodynamic stability. - **Transplantation**: There is a strong emphasis on early liver transplant evaluation. The approach follows a "transplant or die" paradigm for high-grade ACLF, as transplantation is often the definitive treatment for survival. - **Focus**: Systemic support and transplant-centered care. #### **Eastern Perspective: APASL** - **Medical Management and Liver Regeneration**: - **Antiviral Therapy**: For HBV flares, antiviral agents are used to control the underlying hepatic insult. - **Albumin Infusions**: To improve circulatory dysfunction and reduce inflammation. - **Plasma Exchange**: Used in some centers to support liver function and remove toxins. - **Stem-Cell/Regenerative Therapies**: Experimental approaches are employed in select centers to promote liver regeneration. - **Transplantation**: While liver transplantation is important, access to transplantation is often limited in resource-constrained settings. As a result, there is greater focus on bridging and rescue therapies. - **Focus**: Liver-centric management and regeneration-friendly approaches. --- ### **3. Why This Contrast Matters** Understanding the differences between Eastern and Western approaches to ACLF is crucial for a comprehensive perspective on the disease. Here’s why: #### **Recognition of ACLF Across Different Etiologies** - In Asia, HBV-related ACLF is more prevalent, whereas alcohol-related ACLF and metabolic dysfunction-associated liver disease (MASLD, formerly NAFLD) are more common in the West. - Recognizing the specific triggers and etiologies helps tailor early diagnosis and interventions. #### **Adaptation to Resource-Limited Settings** - In regions where liver transplantation is not readily available, Eastern approaches focus on medical management and regenerative therapies as alternatives to transplantation. - Western approaches, on the other hand, emphasize transplantation as the definitive treatment for ACLF. #### **Convergence Toward Unified Management** - Both Eastern and Western perspectives are gradually converging toward a phenotype-based, transplant-aware approach to ACLF. - There is growing interest in combining liver regeneration strategies with systemic support for multiorgan failure. --- ### **Conclusion** The contrasting perspectives from the East and West highlight the complexity of ACLF as a global health challenge. While the East focuses on liver-centric mechanisms and regeneration, the West emphasizes systemic multiorgan failure and transplantation. Understanding these differences enables clinicians to: - Recognize ACLF early, regardless of etiology. - Adapt management strategies based on available resources. - Work toward a unified, patient-centered approach to ACLF care.

Management of alcohol use disorder in alcohol-related liver disease

Management of alcohol use disorder (AUD) in alcohol-related liver disease (ArLD) is a critical component of improving patient outcomes and preventing the progression of liver damage. The coexistence of AUD and ArLD presents unique challenges, as effective management requires addressing both the addiction and the liver disease in an integrated and comprehensive manner. Below is a detailed overview of the management strategies: ### 1. **Importance of AUD Treatment in ArLD** - AUD is the primary driver of ArLD progression, and abstinence from alcohol is the cornerstone of treatment. - Treating AUD can halt or even reverse the progression of ArLD, particularly in the early stages of the disease. - Despite the proven benefits, AUD treatment is underutilized in patients with ArLD, with fewer than 20% receiving any form of treatment and less than 2% being prescribed pharmacotherapy. --- ### 2. **Approaches to Management** #### a) **Medical Addiction Therapy** - **Benefits**: Medical therapies for AUD have been shown to reduce binge drinking, hospitalizations, and the risk of hepatic decompensation. - **Pharmacotherapies**: Several medications are available for treating AUD, but their use in ArLD requires careful consideration due to potential hepatotoxicity, renal excretion, and central nervous system (CNS) effects. - **Naltrexone**: Effective for reducing alcohol cravings but should be avoided in patients with acute liver failure or advanced liver disease due to hepatotoxicity. - **Acamprosate**: A safe option for patients with liver disease as it is primarily excreted by the kidneys, but it should be avoided in those with significant renal impairment. - **Disulfiram**: Generally not recommended in ArLD due to the risk of hepatotoxicity. - **Baclofen**: A promising option for patients with ArLD as it is not metabolized by the liver and has shown efficacy in promoting abstinence. - **Monitoring**: Liver function tests and renal function should be closely monitored during pharmacotherapy. #### b) **Psychotherapy** - Psychotherapeutic interventions are essential in managing AUD and improving liver-related outcomes. - **Cognitive Behavioral Therapy (CBT)**: Helps patients identify and manage triggers for alcohol use. - **Motivational Enhancement Therapy (MET)**: Focuses on enhancing motivation to change drinking behavior. - **12-Step Programs and Support Groups**: Provide peer support and accountability. - Evidence suggests that psychotherapy is associated with lower rates of hepatic decompensation and better overall outcomes. #### c) **Integrated Care Models** - Integrated care involves embedding AUD treatment within liver clinics, rather than relying on standard referrals to addiction services. - **Benefits**: - Improves patient engagement and adherence to treatment. - Increases abstinence rates. - Leads to better clinical outcomes, including reduced progression of liver disease. - Multidisciplinary teams, including hepatologists, addiction specialists, psychologists, and social workers, are key to the success of integrated care models. --- ### 3. **Challenges in Management** - **Stigma**: Patients with AUD often face stigma, which can deter them from seeking or adhering to treatment. - **Practitioner Confidence**: Hepatology and gastroenterology practitioners may lack confidence or training in managing coexisting AUD and ArLD. - **Comorbidities**: Patients with ArLD often have other medical and psychiatric comorbidities that complicate treatment. - **Limited Access**: Access to specialized addiction services and integrated care models may be limited in some settings. --- ### 4. **Benefits of Treating AUD in ArLD** - **Improved Liver Function**: Abstinence can lead to significant improvements in liver function and even reversal of liver damage in early-stage disease. - **Reduced Risk of Complications**: Effective AUD treatment reduces the risk of hepatic decompensation and other complications of advanced liver disease. - **Lower Mortality**: Patients with ArLD who achieve sustained abstinence have significantly lower mortality rates compared to those who continue drinking. --- ### 5. **Future Directions** - Research is needed to optimize treatment strategies for this high-risk population, including: - Identifying the most effective pharmacotherapies for patients with advanced liver disease. - Developing and testing novel integrated care models. - Addressing barriers to care, such as stigma and limited access to addiction treatment. - Personalized treatment approaches that consider the severity of liver disease, comorbidities, and individual patient needs are essential. --- ### 6. **Key Takeaways** - AUD treatment is fundamental to the management of ArLD and significantly improves outcomes. - A combination of pharmacological and psychological therapies, tailored to the individual patient’s needs, is the most effective approach. - Integrated care models that combine AUD treatment with liver disease management offer the best outcomes in terms of patient engagement, abstinence, and clinical results. - Addressing barriers to care and increasing practitioner confidence in managing AUD and ArLD are critical to improving treatment uptake and outcomes. By addressing AUD in patients with ArLD through a multidisciplinary and patient-centered approach, it is possible to reduce the burden of liver disease, improve quality of life, and extend survival.

Esophagogastric Variceal Bleeding in Cirrhotic Portal Hypertension

Esophagogastric variceal bleeding (EVB) is a critical and potentially life-threatening complication of cirrhotic portal hypertension, resulting from elevated portal venous pressure due to liver cirrhosis. Understanding the pathophysiology, diagnosis, management, and prevention of EVB is essential for improving patient outcomes. Here is a comprehensive overview: ### Pathophysiology: - **Portal hypertension**: Cirrhosis leads to increased resistance to portal blood flow, causing elevated portal pressure. This results in the development of gastroesophageal varices as collateral pathways to relieve pressure. - **Variceal rupture**: The high-pressure varices, particularly in the esophagus and stomach, are prone to rupture, leading to significant upper gastrointestinal bleeding. This is the deadliest complication of portal hypertension. --- ### Staging of Cirrhosis and Risk Stratification: - **Compensated cirrhosis (Stages 1–2)**: Patients have no or minimal complications, and the risk of variceal bleeding is lower. - **Decompensated cirrhosis (Stages 3–5)**: Patients develop complications such as variceal bleeding, ascites, or hepatic encephalopathy. Variceal bleeding risk increases significantly. - **Late decompensated cirrhosis (Stage 6)**: Associated with very high mortality rates. --- ### Diagnosis: 1. **Noninvasive Tools**: - Liver stiffness measurement (LSM) using transient elastography: - **LSM >25 kPa** or **20–25 kPa with low platelet count (<150,000/μL)** strongly suggests clinically significant portal hypertension (CSPH). - **LSM <15 kPa with normal platelets** rules out CSPH. 2. **Gastroscopy**: - **Gold standard** for diagnosing varices. - Detects and grades varices based on size, presence of red wale signs, and bleeding risk. - Severity classification: - **Mild**: Straight veins. - **Moderate**: Tortuous veins or red color (RC+) signs. - **Severe**: Beady or tumor-like veins with high rupture potential. 3. **LDRf Classification**: - A Chinese system based on **Location (L)**, **Diameter (D)**, and **Risk factors (Rf)** to guide treatment selection and timing. --- ### Management of Acute Esophagogastric Variceal Bleeding (AEVB): 1. **Initial Stabilization**: - ICU admission for hemodynamic monitoring and airway protection. - **Restrictive blood transfusion** targeting hemoglobin levels of 70–80 g/L. - Correct coagulopathy if needed. 2. **Pharmacologic Therapy**: - **Vasoactive drugs** (first-line therapy): - Terlipressin, somatostatin, or octreotide, administered for 3–5 days to reduce portal pressure and control bleeding. - **Prophylactic antibiotics**: - Cephalosporins (e.g., ceftriaxone) reduce the risk of infections, early rebleeding, and mortality, especially in Child-Pugh B/C patients. 3. **Endoscopic Therapy**: - **Esophageal varices**: - Endoscopic variceal ligation (EVL) is the primary treatment. - Endoscopic injection sclerotherapy (EIS) is used if EVL is not feasible. - **Gastric varices**: - Tissue glue injection (e.g., cyanoacrylate) is the first-line therapy. - Endoscopic ultrasound (EUS)-guided therapy improves outcomes by achieving superior occlusion rates and reducing recurrence. 4. **Rescue Therapy**: - **Sengstaken-Blakemore tube**: - Temporary measure for uncontrolled bleeding when EVL or TIPS is unavailable. It carries high rebleeding and complication rates. - **TIPS (Transjugular Intrahepatic Portosystemic Shunt)**: - Definitive rescue therapy for refractory bleeding. - Early or preemptive TIPS (pTIPS) within 72 hours is beneficial for high-risk patients: - Child-Pugh B with active bleeding. - Child-Pugh C (<14 points) with HVPG >20 mmHg. --- ### Prevention Strategies: #### 1. **Primary Prevention** (Preventing the first bleed): - **Treating the underlying cause of cirrhosis**: - Antiviral therapy for HBV/HCV. - Managing alcohol-related liver disease and nonalcoholic steatohepatitis (NASH). - Traditional Chinese medicine (TCM) formulas may help slow fibrosis and reduce portal pressure. - **Nonselective beta-blockers (NSBB)**: - Not recommended for patients without varices (do not prevent varice formation). - Recommended for mild varices with high-risk features (e.g., Child-Pugh B/C or RC+ signs). Options include propranolol or carvedilol. - **Moderate-severe varices**: - NSBB or EVL can lower the risk of the first bleed. - EVL is preferred if NSBB are contraindicated or not tolerated. - **Carvedilol**: - More potent than propranolol, reducing hepatic venous pressure gradient (HVPG) by up to 20%. #### 2. **Secondary Prevention** (Preventing rebleeding after the first episode): - Initiate within 5 days of the initial bleed. - Combination of **NSBB (e.g., carvedilol)** and **EVL** is the standard approach. - TIPS is considered for patients with persistent high-risk features or recurrent bleeding despite optimal therapy. --- ### Prognosis: - **First EVB episode**: High mortality risk, requiring emergency management. - **Late-stage cirrhosis**: Patients in stages 5–6 have poor outcomes, emphasizing the need for aggressive prevention and timely intervention. --- ### Key Takeaways: - EVB is a medical emergency that requires a multidisciplinary approach, including pharmacologic, endoscopic, and sometimes surgical interventions. - Early diagnosis and risk stratification using noninvasive tools and gastroscopy are critical. - Preventive strategies, including NSBB, EVL, and addressing the underlying cause of cirrhosis, are essential to reduce morbidity and mortality. - TIPS is an effective rescue therapy for refractory bleeding but is reserved for high-risk patients due to the increased risk of hepatic encephalopathy.

Breath Biopsy

Breath Biopsy refers to a cutting-edge, non-invasive diagnostic technique that analyzes volatile organic compounds (VOCs) present in exhaled breath to detect metabolic changes associated with various diseases, including liver conditions such as cirrhosis. This approach leverages the fact that VOCs are byproducts of metabolic processes, and their composition can change due to disease-related dysfunctions in the body. Breath Biopsy offers a promising alternative to traditional methods, providing earlier detection, disease staging, and insights into underlying metabolic alterations. ### Key Features and Insights from Breath Biopsy in Cirrhosis: 1. **Non-Invasive Diagnostic Tool**: - Breath Biopsy provides a non-invasive method to detect liver disease by analyzing exhaled VOCs, which reflect metabolic changes in the body. - It eliminates the need for invasive procedures like liver biopsies or blood tests, making it patient-friendly. 2. **Study Setup**: - A study compared exhaled breath samples from 46 cirrhosis patients and 42 healthy controls using standardized Breath Biopsy OMNI™ GC-MS technology. - This advanced technology ensured high accuracy in identifying and quantifying VOCs. 3. **VOC Biomarker Identification**: - Out of the VOCs analyzed, 29 compounds significantly differed between cirrhosis patients and controls, forming the basis for biomarker discovery. - Seven specific VOCs provided optimal diagnostic accuracy: limonene, 2-pentanone, eucalyptol, dimethyl selenide, indole, an alkene, and an alkylbenzene. 4. **Diagnostic Accuracy**: - A classification model based on the seven VOCs achieved excellent diagnostic performance, with a cross-validated area under the curve (AUC) of 0.95±0.04. - This accuracy was notably higher than using limonene alone, demonstrating the superiority of multi-VOC panels over single biomarkers. 5. **Metabolic Insights from VOCs**: - Elevated levels of **limonene** and **2-pentanone** were linked to decreased CYP2C9/2C19 metabolism and impaired hepatic clearance in cirrhosis. - Reduced levels of **dimethyl selenide** reflected altered selenium metabolism and impaired detoxification pathways. - Increased levels of **indole** were associated with gut microbiota overproduction and reduced hepatic clearance. 6. **Correlation with Liver Function**: - Eleven VOCs showed strong correlations with liver function tests, including bilirubin, albumin, and INR, highlighting their functional relevance. - Limonene exhibited the strongest clinical correlation, positively correlating with bilirubin/INR and inversely with albumin, indicating worsening liver function. 7. **Disease Staging Capability**: - Principal Component Analysis (PCA) revealed that VOC changes could distinguish cirrhosis severity. For example, Child-Pugh B patients clustered away from healthy controls, suggesting potential for staging liver disease. 8. **Environmental Factors and Quality Control**: - Rigorous blank and quality-control procedures excluded environmental contaminants, ensuring reliable identification of true breath biomarkers. - Standardized breath collection methods, including purified inhaled air and controlled sampling, reduced measurement noise and improved accuracy. 9. **Influence of Comorbidities**: - Certain VOCs were influenced by comorbid conditions: - Portal hypertension increased limonene and 2-pentanone levels. - Obesity elevated indole levels. 10. **Superiority of Multi-VOC Panels**: - A multi-VOC panel outperformed single biomarkers, capturing the complexity of metabolic changes in cirrhosis and providing a more comprehensive diagnostic signature. ### Advantages of Breath Biopsy: - **Early Detection**: VOC analysis can detect cirrhosis earlier than traditional methods, potentially improving patient outcomes. - **Non-Invasive and Convenient**: Breath sampling is simple, painless, and can be performed repeatedly for monitoring purposes. - **Functional Insights**: VOC changes provide direct insights into impaired liver metabolism and detoxification pathways. - **Potential for Disease Staging**: Breath Biopsy can help stratify patients by disease severity, aiding in clinical decision-making. ### Limitations and Future Directions: - **Influence of Comorbidities**: VOC levels can be affected by conditions like obesity or portal hypertension, requiring careful interpretation. - **Standardization**: While standardized breath capture methods have improved accuracy, further refinement is needed for widespread clinical adoption. - **Biomarker Validation**: Larger-scale studies are required to validate the identified VOCs and ensure reproducibility across diverse populations. ### Conclusion: Breath Biopsy represents a transformative diagnostic tool for liver diseases like cirrhosis. By analyzing exhaled VOCs, it provides a non-invasive, accurate, and functional assessment of metabolic dysfunction. With continued research and technological advancements, Breath Biopsy has the potential to revolutionize disease detection, staging, and management in clinical practice.